GLPwatch
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
NCT00701935 · Terminated
Last updated 2026-05-28This clinical trial tested whether the medication exenatide reduces abdominal fat in adults with type 2 diabetes who are already taking metformin.
Status Terminated Stopped early and will not restart.
Phase Phase 2 Tests whether it works and watches safety in a moderate group.
Type Interventional (clinical trial)
Design Randomized, double-blind treatment study
Participants 80 people
Who can join Ages 18–85 · all sexes
Timeline Started 2008-08 · est. completion 2012-01
Where 17 sites · Canada, United States
What this study is testing ClinicalTrials.gov NCT00701935 ↗
Description as written by the study sponsor.
A multicenter, randomized, double-blind, placebo-controlled trial will assess the effects of twice-daily subcutaneous injection with exenatide versus treatment with matching placebo injection on abdominal visceral fat content.
Treatments tested
- placebo Drug
subcutaneous injection, twice a day
- exenatide Drug
subcutaneous injection, twice a day, 10mcg
| Main thing measured | Percentage Change in Abdominal Visceral Fat From Baseline to 6 Months |
|---|---|
| Sponsor | AstraZeneca |
| Conditions studied | Diabetes Mellitus |
| GLP-1 drugs | exenatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00701935 ↗